- Acitretin, a synthetic retinoid primarily used for the treatment of severe psoriasis and other skin disorders, is gaining prominence due to its long-term efficacy, particularly in cases unresponsive to topical treatments or phototherapy
- The escalating demand for Acitretin is primarily fueled by increasing incidences of chronic dermatological conditions, greater patient awareness, and improved healthcare access, especially in emerging economies. Rising dermatology consultations and expanding healthcare coverage are also driving prescription rates
- North America dominated the acitretin market with the largest revenue share of 38.60% in 2024, driven by high diagnosis rates of psoriasis, access to advanced dermatological care, and the presence of major pharmaceutical manufacturers. In the U.S., adoption is reinforced by continuous drug innovation, improved reimbursement frameworks, and the rising prevalence of autoimmune skin conditions
- Asia-Pacific is expected to be the fastest-growing region in the acitretin market during the forecast period, with a CAGR of 7.9% from 2025 to 2032, owing to rapid urbanization, increasing disposable incomes, and growing awareness of skin health. Countries such as India, China, and Japan are contributing significantly to regional growth through the expansion of generic drug manufacturing and dermatology infrastructure
- The psoriasis segment dominated the acitretin market with a market share of 61.9% in 2024, due to Acitretin’s established role in managing severe and chronic plaque psoriasis. Its long-term efficacy, particularly among patients who do not respond to biologic therapies, reinforces its clinical relevance and widespread adoption in dermatological practice
